Botanical species · safety record

Magnolia officinalis

The EFSA Compendium of Botanicals holds 11 constituent measurements for Magnolia officinalis. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Magnolia officinalis Rehder & E.H. Wilson

11Constituent measurements

0Safety records

4Cited sources

750Licensed products (Canada)

Regulatory presence

Health Canada's Licensed Natural Health Products Database holds 750 licensed products naming Magnolia officinalis as a medicinal ingredient, matched on the exact Latin binomial. A licence records that a product met the regulator's requirements for sale in Canada. It is not evidence that the product works.

Extract types on licence

Dry
Extract Type TBA
decoction
solid

Source material stated

Aged bark
Bark
Bark (processed with ginger)
Bark extract
Bark of branches
Bark of dried stem
Branch bark
Cortex

What the records describe

Constituents measured

Plant parts

Preparations

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

Substance	Plant part	Preparation	Concentration	Analytical method	Source
Aporphine alkaloids	Bark	Solvent extraction	—	UHPLC-MS-MS	Resolve DOI
Aporphine alkaloids	Bark	Solvent extraction	—	UHPLC-MS-MS	Resolve DOI
Honokiol	Bark	Solvent extraction	—	Colorimetry, Spectroscopy (Spectrometry) and Photometry	Resolve DOI
Honokiol	Bark	Solvent extraction	1.5 Percent	High Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)	Resolve DOI
Isoquinoline alkaloids	Bark	Solvent extraction	—	UHPLC-MS-MS	Resolve DOI
Magnocurarine	Bark	Solvent extraction	—	UHPLC-MS-MS	Resolve DOI
Magnoflorine	Bark	Solvent extraction	—	UHPLC-MS-MS	Resolve DOI
Magnolol	Bark	Solvent extraction	—	Colorimetry, Spectroscopy (Spectrometry) and Photometry	Resolve DOI
Magnolol	Bark	Solvent extraction	94 Percent	High Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)	Resolve DOI
Neolignans	Bark	Solvent extraction	—	Colorimetry, Spectroscopy (Spectrometry) and Photometry	Resolve DOI
Neolignans	Bark	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	Resolve DOI

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

KONOSHIMA, T., KOZUKA, M., TOKUDA, H., NISHINO, H., IWASHIMA, A., HARUNA, M., ITO, K., TANABE, M. STUDIES ON INHIBITORS OF SKIN TUMOR PROMOTION .9. NEOLIGNANS FROM MAGNOLIA-OFFICINALIS. Journal of natural products, 1991, vol. 54, no. 3, p. 816-822. DOI
Li, N., Song, Y., Zhang, W., Wang, W., Chen, J., Wong, A.W., Roberts, A. Evaluation of the in vitro and in vivo genotoxicity of magnolia bark extract. Regulatory toxicology and pharmacology, 2007, vol. 49, no. 3, p. 154-159. DOI
Oh, Ju Hoon., Ban, Jung Ok., Cho, Min-Chul., Jo, Miran., Jung, Jae Kyung., Ahn, Byeongwoo., Yoon, Do-Young., Han, Sang Bae., Hong, Jin Tae. 4-O-methylhonokiol inhibits colon tumor growth via p21-mediated suppression of NF-kappa B activity. Journal of nutritional biochemistry, 2012, vol. 23, no. 7, p. 706-715. DOI
Yan, Renyi., Wang, Weihao., Guo, Jian., Liu, Hongliang., Zhang, Jianyong., Yang, Bin. Studies on the Alkaloids of the Bark of Magnolia officinalis: Isolation and On-line Analysis by HPLC-ESI-MSn. Molecules, 2013, vol. 18, no. 7, p. 7739-7750. DOI

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue

Independent literature